Abbvie Inc
NYSE: ABBV
$178.41
+$1.46 (+0.8%)
Real Time Data Delayed 15 Min.
ABBV Articles
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
We screened the Jefferies Franchise Pick List for top stocks rated Buy with the highest upside to the Jefferies price targets.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Published:
AT&T continued to reign as the most shorted stock trading on the New York Stock Exchange between the May 15 and May 29 settlement dates.
Published:
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Published:
Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
Published:
ThinkstockThe American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across the health care sector flock to this conference to...
Published:
The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short interest is mixed.
Published:
Wednesday's top analyst upgrades, downgrades and initiations include Ambarella, eBay, Rite Aid, TiVo, Yahoo, Valero Energy and Virtu Financial.
Published:
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair...
Published:
The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the right time to add biotech stocks.
Published:
Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.
Published:
A new report from Deutsche Bank highlights all of the known risks and focuses in on stocks that are reasonable in a pricey market.
Published:
Last Updated:
In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising first-quarter earnings.
Published: